PLXND1 and posterior cortical atrophy: Concordantly, analysis of two independent PCa datasets showed increased PLXND1 mRNA levels in tumors from patients who had biochemical recurrence [GSE21032 (Taylor et al, 2010) (Data ref: Taylor et al, 2010)] as well as in hormone-refractory tumors [GSE6099 (Tomlins et al, 2007) (Data ref: Tomlins et al, 2007)] compared with respective controls (Fig. 2E).